The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study
Objective:To assess the impact of baseline body mass index (BMI) on the efficacy and retention of intravenous abatacept at 6 months in biologic-naïve patients with rheumatoid arthritis (RA). Methods: This was a 6-month analysis of a 2-year, non-interventional, international, prospective study. Base...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Joint bone spine
Year: 2016, Jahrgang: 84, Heft: 5, Pages: 571-576 |
| ISSN: | 1778-7254 |
| DOI: | 10.1016/j.jbspin.2016.10.011 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.jbspin.2016.10.011 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1297319X1630210X 
|
| Verfasserangaben: | Xavier Mariette, Rieke Alten, Hubert G. Nüßlein, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581496451 | ||
| 003 | DE-627 | ||
| 005 | 20220815023128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181002r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jbspin.2016.10.011 |2 doi | |
| 035 | |a (DE-627)1581496451 | ||
| 035 | |a (DE-576)511496451 | ||
| 035 | |a (DE-599)BSZ511496451 | ||
| 035 | |a (OCoLC)1341019568 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mariette, Xavier |e VerfasserIn |0 (DE-588)1168273498 |0 (DE-627)1031923160 |0 (DE-576)51149615X |4 aut | |
| 245 | 1 | 4 | |a The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis |b 6-month results from the 2-year, observational, prospective ACTION study |c Xavier Mariette, Rieke Alten, Hubert G. Nüßlein, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars |
| 264 | 1 | |c 2017 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 30 December 2016 | ||
| 500 | |a Gesehen am 02.10.2018 | ||
| 520 | |a Objective:To assess the impact of baseline body mass index (BMI) on the efficacy and retention of intravenous abatacept at 6 months in biologic-naïve patients with rheumatoid arthritis (RA). Methods: This was a 6-month analysis of a 2-year, non-interventional, international, prospective study. Baseline characteristics, clinical response and retention rates were compared by BMI subgroup: underweight/normal, overweight and obese (<25, 25 to <30 and ≥30kg/m2, respectively). Results: BMI was reported in 643/672 (96%) patients: 264 (41%) were underweight/normal, 224 (35%) overweight and 155 (24%) obese. At baseline, the obese group had more active disease (mean [95% confidence intervals] 28-joint Disease Activity Score [C-reactive protein; derived] 4.6 [4.5, 4.7], 4.8 [4.7, 5.0] and 5.1 [4.9, 5.2] for underweight/normal, overweight and obese groups, respectively), a higher prevalence of metabolic disorders, a greater proportion of women and a lower proportion of patients with rheumatoid factor positivity. There were no significant differences in the percentages of patients achieving a good/moderate European League Against Rheumatism response by BMI group (80.7, 86.1 and 77.0% for underweight/normal, overweight and obese groups, respectively; P=0.178). Overall retention rates at 6 months did not differ across groups (89, 92 and 89% for underweight/normal, overweight and obese groups, respectively; log-rank P=0.382). After adjustment for baseline characteristics, BMI was not significantly associated with risk of discontinuation (reference BMI<25kg/m2; hazard ratio [95% confidence intervals] 0.46 [0.22, 0.99] and 0.69 [0.34, 1.41] for overweight and obese patients, respectively). Conclusion: BMI does not impact abatacept clinical response or retention in biologic-naïve patients with RA. | ||
| 534 | |c 2016 | ||
| 650 | 4 | |a Abatacept | |
| 650 | 4 | |a Body mass index | |
| 650 | 4 | |a EULAR response | |
| 650 | 4 | |a Real-world study | |
| 650 | 4 | |a Retention rate | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 700 | 1 | |a Lorenz, Hanns-Martin |d 1962- |e VerfasserIn |0 (DE-588)112253865 |0 (DE-627)627277845 |0 (DE-576)167601369 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Joint bone spine |d Paris : Elsevier, 2000 |g 84(2017), 5, Seite 571-576 |h Online-Ressource |w (DE-627)335259820 |w (DE-600)2059233-4 |w (DE-576)271360801 |x 1778-7254 |7 nnas |a The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis 6-month results from the 2-year, observational, prospective ACTION study |
| 773 | 1 | 8 | |g volume:84 |g year:2017 |g number:5 |g pages:571-576 |g extent:6 |a The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis 6-month results from the 2-year, observational, prospective ACTION study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jbspin.2016.10.011 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1297319X1630210X |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181002 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 112253865 |a Lorenz, Hanns-Martin |m 112253865:Lorenz, Hanns-Martin |d 910000 |d 910100 |e 910000PL112253865 |e 910100PL112253865 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1581496451 |e 3027591096 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1016/j.jbspin.2016.10.011"],"eki":["1581496451"]},"language":["eng"],"relHost":[{"title":[{"subtitle":"revue du rhumatisme, international edition ; official publication of the French Society of Rheumatology","title":"Joint bone spine","title_sort":"Joint bone spine"}],"titleAlt":[{"title":"Revue du rhumatisme / International edition"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"6","year":"2017","issue":"5","volume":"84","text":"84(2017), 5, Seite 571-576","pages":"571-576"},"origin":[{"dateIssuedDisp":"2000-","publisherPlace":"Paris","dateIssuedKey":"2000","publisher":"Elsevier"}],"id":{"eki":["335259820"],"zdb":["2059233-4"],"issn":["1778-7254"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["67.2000 -"],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 13.02.20"],"recId":"335259820","disp":"The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis 6-month results from the 2-year, observational, prospective ACTION studyJoint bone spine"}],"physDesc":[{"extent":"6 S."}],"person":[{"display":"Mariette, Xavier","family":"Mariette","given":"Xavier","role":"aut"},{"display":"Lorenz, Hanns-Martin","family":"Lorenz","given":"Hanns-Martin","role":"aut"}],"title":[{"title_sort":"effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis","title":"The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis","subtitle":"6-month results from the 2-year, observational, prospective ACTION study"}],"recId":"1581496451","note":["Available online 30 December 2016","Gesehen am 02.10.2018"],"name":{"displayForm":["Xavier Mariette, Rieke Alten, Hubert G. Nüßlein, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars"]}} | ||
| SRT | |a MARIETTEXAEFFECTOFBO2017 | ||